Juan Ruiz has joined New York gene therapy developer Abeona Therapeutics (NASDAQ: [[ticker:ABEO]]) as chief medical officer. Ruiz’s experience includes executive positions at Lykera Biomed and Digna Biotech, both Spain-based companies. Abeona’s lead drugs are gene therapy candidates for the rare enzyme deficiency disorder Sanfilippo syndrome type A, and epidermolysis bullosa, which is a rare genetic disease that leads to fragile skin that easily wounds and blisters.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
